

**CD39/ECTO-ADPASE FOR TREATMENT  
OF THROMBOTIC AND ISCHEMIC DISORDERS**

**Abstract of the Disclosure**

5

The present invention provides a method of treating or preventing thrombotic or ischemic disorders in a subject which comprises administering an agent to the subject, wherein the agent inhibits ADP-mediated platelet aggregation by increasing ADP catabolism, and a method for determining whether a compound inhibits platelet aggregation by increasing ADP catabolism so as to treat or prevent thrombotic or ischemic disorders in a subject, comprising: (a) inducing thrombotic or ischemic disorders in an animal, which animal is an animal model for thrombotic or ischemic disorders; (b) measuring the stroke outcome in said animal, (c) measuring platelet deposition and/or fibrin deposition in ischemic tissue, and (d) comparing the stroke outcome in step (b) and the platelet deposition and/or fibrin deposition with that of the animal model in the absence of the compound so as to identify a compound capable of treating or preventing thrombotic or ischemic disorders in a subject.

25